Recorded on 3/13/2021
70-year-old female with recurrent adenocarcinoma following right pneumectomy, hemithorax radiation and stereotactic body radiation to the left lung twice, currently on osimertinib
Summary:
- Prior radiotherapy does not preclude additional courses; when assessing whether repeat radiotherapy is contraindicated, what matters is the effective dose to critical structures such as the airway or blood vessels
- Proton therapy or SBRT may be considered for reirradiation
- The mechanism of acquired resistance should be determined via tissue sampling prior to recommending a switch in immunotherapy, as acquired resistance following osimertinib may be due to a multitude of mutations. If this cannot be ascertained, cytotoxic chemotherapy is the next step, with a regimen of carboplatin and pemetrexed recommended with continued osimertinib.
- Bevacizumab may be considered as an adjunct, but there are no data to support its use at this time.
At PrecisCa, we are dedicated to providing expert second opinions for cancer patients to ensure they receive the best possible care. Our videos cover a wide range of topics related to oncology, including in-depth discussions on different types of cancer, treatment options, patient stories, and the latest advancements in cancer research. Whether you're a patient, caregiver, or simply seeking to expand your knowledge, our goal is to support you on your healthcare journey.
Visit our website: https://www.PrecisCa.com for more detailed information and personalized second opinions.
Stay connected with us:
Facebook: / precisca.oncology
Twitter: https://twitter.com/precisca_?lang=en
-Instagram: / precisca_oncology
-LinkedIn: / precisca
Don't forget to subscribe to our channel for regular updates and new videos. Hit the bell icon to receive notifications every time we upload. #Oncology #CancerCare #CancerSupport #CancerResearch #Health #Healthcare #CancerTreatment #CancerAwareness #PatientCare #MedicalAdvice #PrecisCa
70-year-old female with recurrent adenocarcinoma following right pneumectomy, hemithorax radiation and stereotactic body radiation to the left lung twice, currently on osimertinib
Summary:
- Prior radiotherapy does not preclude additional courses; when assessing whether repeat radiotherapy is contraindicated, what matters is the effective dose to critical structures such as the airway or blood vessels
- Proton therapy or SBRT may be considered for reirradiation
- The mechanism of acquired resistance should be determined via tissue sampling prior to recommending a switch in immunotherapy, as acquired resistance following osimertinib may be due to a multitude of mutations. If this cannot be ascertained, cytotoxic chemotherapy is the next step, with a regimen of carboplatin and pemetrexed recommended with continued osimertinib.
- Bevacizumab may be considered as an adjunct, but there are no data to support its use at this time.
At PrecisCa, we are dedicated to providing expert second opinions for cancer patients to ensure they receive the best possible care. Our videos cover a wide range of topics related to oncology, including in-depth discussions on different types of cancer, treatment options, patient stories, and the latest advancements in cancer research. Whether you're a patient, caregiver, or simply seeking to expand your knowledge, our goal is to support you on your healthcare journey.
Visit our website: https://www.PrecisCa.com for more detailed information and personalized second opinions.
Stay connected with us:
Facebook: / precisca.oncology
Twitter: https://twitter.com/precisca_?lang=en
-Instagram: / precisca_oncology
-LinkedIn: / precisca
Don't forget to subscribe to our channel for regular updates and new videos. Hit the bell icon to receive notifications every time we upload. #Oncology #CancerCare #CancerSupport #CancerResearch #Health #Healthcare #CancerTreatment #CancerAwareness #PatientCare #MedicalAdvice #PrecisCa
- Category
- Oncology

Be the first to comment